What is ADVATE? ADVATE® is a medicine used to replace clotting factor (factor VIII or
antihemophilic factor) that is missing in people with hemophilia A. ADVATE is not used to treat von Willebrand disease.1
*In clinical trials, ADVATE has demonstrated the ability to help patients prevent bleeding episodes using a prophylaxis regimen.
For people with hemophilia A, ADVATE has a legacy of treatment experience and provides clinically proven bleed protection.*1,2
Data on file. Takeda Pharmaceutical Company Limited. 2018.
Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A. Haemophilia. 2015;21(6):791-798.
myPKFiT for Healthcare Professionals v3.3 User Manual. 2019.
Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):607-615.
You are now leaving ADVATE.com
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.